News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,901 Results
Type
Article (40376)
Company Profile (255)
Press Release (669260)
Multimedia
Podcasts (72)
Webinars (15)
Section
Business (204486)
Career Advice (2015)
Deals (35480)
Drug Delivery (100)
Drug Development (81281)
Employer Resources (172)
FDA (16309)
Job Trends (14910)
News (345961)
Policy (32717)
Tag
Academia (2558)
Accelerated approval (14)
Adcomms (24)
Allergies (108)
Alliances (49604)
ALS (125)
Alzheimer's disease (1552)
Antibody-drug conjugate (ADC) (169)
Approvals (16357)
Artificial intelligence (352)
Autoimmune disease (39)
Automation (23)
Bankruptcy (361)
Best Places to Work (11638)
BIOSECURE Act (19)
Biosimilars (132)
Biotechnology (174)
Bladder cancer (111)
Brain cancer (39)
Breast cancer (408)
Cancer (3283)
Cardiovascular disease (266)
Career advice (1689)
Career pathing (32)
CAR-T (203)
CDC (37)
Cell therapy (544)
Cervical cancer (27)
Clinical research (67482)
Collaboration (1174)
Company closure (4)
Compensation (832)
Complete response letters (36)
COVID-19 (2658)
CRISPR (66)
C-suite (471)
Cystic fibrosis (120)
Data (3670)
Decentralized trials (2)
Denatured (22)
Depression (79)
Diabetes (386)
Diagnostics (6487)
Digital health (27)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (161)
Drug pricing (136)
Drug shortages (28)
Duchenne muscular dystrophy (171)
Earnings (88547)
Editorial (44)
Employer branding (21)
Employer resources (148)
Events (114617)
Executive appointments (888)
FDA (18437)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1041)
Gene editing (146)
Generative AI (25)
Gene therapy (428)
GLP-1 (836)
Government (4577)
Grass and pollen (5)
Guidances (330)
Healthcare (18853)
HIV (42)
Huntington's disease (31)
IgA nephropathy (47)
Immunology and inflammation (182)
Immuno-oncology (13)
Indications (45)
Infectious disease (2850)
Inflammatory bowel disease (162)
Inflation Reduction Act (10)
Influenza (77)
Intellectual property (156)
Interviews (314)
IPO (16611)
IRA (48)
Job creations (3640)
Job search strategy (1424)
Kidney cancer (13)
Labor market (63)
Layoffs (523)
Leadership (22)
Legal (7942)
Liver cancer (84)
Longevity (11)
Lung cancer (476)
Lymphoma (242)
Machine learning (22)
Management (58)
Manufacturing (505)
MASH (106)
Medical device (13557)
Medtech (13574)
Mergers & acquisitions (19670)
Metabolic disorders (941)
Multiple sclerosis (110)
NASH (16)
Neurodegenerative disease (158)
Neuropsychiatric disorders (37)
Neuroscience (2355)
NextGen: Class of 2025 (6518)
Non-profit (4493)
Now hiring (53)
Obesity (461)
Opinion (230)
Ovarian cancer (110)
Pain (136)
Pancreatic cancer (141)
Parkinson's disease (198)
Partnered (24)
Patents (362)
Patient recruitment (259)
Peanut (52)
People (58015)
Pharmaceutical (62)
Pharmacy benefit managers (21)
Phase I (20996)
Phase II (29722)
Phase III (22119)
Pipeline (2377)
Policy (231)
Postmarket research (2570)
Preclinical (8946)
Press Release (64)
Prostate cancer (161)
Psychedelics (40)
Radiopharmaceuticals (255)
Rare diseases (519)
Real estate (5933)
Recruiting (66)
Regulatory (23149)
Reports (51)
Research institute (2337)
Resumes & cover letters (350)
Rett syndrome (11)
RNA editing (11)
RSV (55)
Schizophrenia (107)
Series A (171)
Series B (128)
Service/supplier (11)
Sickle cell disease (68)
Special edition (20)
Spinal muscular atrophy (149)
Sponsored (34)
Startups (3596)
State (2)
Stomach cancer (14)
Supply chain (86)
Tariffs (72)
The Weekly (48)
Vaccines (861)
Venture capital (59)
Weight loss (288)
Women's health (51)
Worklife (17)
Date
Today (106)
Last 7 days (421)
Last 30 days (2215)
Last 365 days (30856)
2025 (21568)
2024 (35232)
2023 (40101)
2022 (51194)
2021 (55721)
2020 (54091)
2019 (46557)
2018 (35028)
2017 (32110)
2016 (31486)
2015 (37555)
2014 (31324)
2013 (26361)
2012 (28583)
2011 (29280)
2010 (27337)
Location
Africa (724)
Alabama (69)
Alaska (7)
Arizona (258)
Arkansas (13)
Asia (38552)
Australia (6271)
California (8523)
Canada (2634)
China (772)
Colorado (356)
Connecticut (362)
Delaware (224)
Europe (82817)
Florida (1273)
Georgia (285)
Hawaii (2)
Idaho (60)
Illinois (679)
India (38)
Indiana (402)
Iowa (17)
Japan (259)
Kansas (114)
Kentucky (31)
Louisiana (16)
Maine (65)
Maryland (1132)
Massachusetts (6232)
Michigan (264)
Minnesota (504)
Mississippi (4)
Missouri (101)
Montana (28)
Nebraska (25)
Nevada (98)
New Hampshire (68)
New Jersey (2328)
New Mexico (28)
New York (2313)
North Carolina (1189)
North Dakota (8)
Northern California (3861)
Ohio (261)
Oklahoma (16)
Oregon (35)
Pennsylvania (1800)
Puerto Rico (17)
Rhode Island (41)
South America (1100)
South Carolina (43)
South Dakota (1)
Southern California (3276)
Tennessee (138)
Texas (1310)
United States (31029)
Utah (252)
Virginia (210)
Washington D.C. (74)
Washington State (706)
West Virginia (4)
Wisconsin (71)
709,901 Results for "eisai inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.
September 2, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Action Alert: Biogen/Eisai, Sanofi, Ionis and More
Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s Alzheimer’s drug Leqembi, which, according to Eisai, could “help reduce the burden on healthcare professionals and patients.”
August 11, 2025
·
5 min read
·
Tristan Manalac
Layoffs
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American headquarters in Nutley, New Jersey. A company spokesperson said the pharma remains fully committed to the U.S. market.
February 28, 2025
·
1 min read
·
Angela Gabriel
Alzheimer’s disease
Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai’s new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
March 26, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Biogen, Eisai’s Leqembi Slows Alzheimer’s Progression Through 4 Years of Treatment
Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the earlier stages of Alzheimer’s disease as compared to the condition’s natural progression.
July 30, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 4, 2025
·
4 min read
Press Releases
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 8, 2025
·
5 min read
Press Releases
Eisai Limited Bolsters Canadian Operations with Major Mississauga Expansion
June 23, 2025
·
3 min read
Press Releases
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
September 2, 2025
·
20 min read
Press Releases
Eisai to Present Four-Year Efficacy and Safety Data on Continuous Treatment with Lecanemab at The Alzheimer’s Association International Conference
July 23, 2025
·
16 min read
1 of 70,991
Next
